J&J Calls Time on Addex Partnership a Year After Epilepsy Fail
Details : J&J has return all development and commercialization rights to ADX71149 (JNJ-40411813), a PAM of mGluR2, and the partnership between the two companies has been terminated.
Product Name : ADX71149
Product Type : Other Small Molecule
Upfront Cash : $4.0 million
April 17, 2025
Lead Product(s) : ADX71149,Levetiracetam
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Addex’s Partner Discontinues ADX71149 development in Epilepsy
Details : ADX71149/JNJ-40411813, is a selective metabotropic glutamate sub-type 2 (mGlu2) receptor positive allosteric modulator being evaluated for the treatment of epilepsy.
Product Name : ADX71149
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 22, 2024
Lead Product(s) : ADX71149,Levetiracetam
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ADX71149,Levetiracetam
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Johnson & Johnson Innovative Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Addex Provides Update on ADX71149 Phase 2 Epilepsy Study
Details : JNJ-40411813 (ADX71149) is a selective metabotropic glutamate subtype 2 (mGlu2) receptor positive allosteric modulator (PAM). It is being evaluated for the treatment of focal onset seizures.
Product Name : ADX71149
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 29, 2024
Lead Product(s) : ADX71149,Levetiracetam
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Johnson & Johnson Innovative Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ADX71149,Levetiracetam
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Addex ADX71149 Epilepsy Phase 2 Study Completes Recruitment of Patients
Details : ADX71149/JNJ-40411813, is a selective metabotropic glutamate sub-type 2 (mGlu2) receptor positive allosteric modulator (PAM) is in a Phase 2 clinical trial for the treatment of epilepsy.
Product Name : ADX71149
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 14, 2023
Lead Product(s) : ADX71149,Levetiracetam
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ADX71149,Levetiracetam
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : GSK
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ADX71149/JNJ-40411813, is a selective metabotropic glutamate sub-type 2 (mGlu2) receptor positive allosteric modulator (PAM) is in a Phase 2 clinical trial for the treatment of epilepsy.
Product Name : ADX71149
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 05, 2023
Lead Product(s) : ADX71149,Levetiracetam
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : GSK
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ADX71149,Levetiracetam
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Addex Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Addex Strategic Partner Completes Enrollment in ADX71149 Epilepsy Phase 2 Study Part 1
Details : ADX71149 (JNJ-40411813) is a novel orally active positive allosteric modulator of metabotropic Glutamate 2 receptor (mGlu2R). It is being developed for the treatment of epilepsy.
Product Name : ADX71149
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 02, 2023
Lead Product(s) : ADX71149,Levetiracetam
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Addex Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ADX71149,Levetiracetam
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : GSK
Deal Size : Inapplicable
Deal Type : Inapplicable
Addex ADX71149 Phase 2 Epilepsy Study Expected to Readout Data in Q2 2024
Details : ADX71149/JNJ-40411813, is a selective metabotropic glutamate sub-type 2 (mGlu2) receptor positive allosteric modulator (PAM) is in a Phase 2 clinical trial for the treatment of epilepsy.
Product Name : ADX71149
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 09, 2023
Lead Product(s) : ADX71149,Levetiracetam
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : GSK
Deal Size : Inapplicable
Deal Type : Inapplicable
Addex Completes $5.0 Million Equity Financing
Details : This financing will support the lead product, ADX71149 (mGlu2 positive allosteric modulator or PAM), developed in collaboration with Janssen, is in a Phase 2a proof of concept clinical trial for the treatment of epilepsy.
Product Name : ADX71149
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 04, 2023
Addex Starts Phase 2 Clinical Study of ADX71149 for Epilepsy
Details : The multi-center study (ClinicalTrials.gov Identifier: NCT04836559) will assess the efficacy, safety, tolerability and pharmacokinetics of adjunctive JNJ-40411813 (ADX71149) administration in patients with focal onset seizures with suboptimal response to...
Product Name : ADX71149
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 06, 2021
Addex to Present at the 10th International Meeting on Metabotropic Glutamate Receptors
Details : JNJ-40411813 (ADX71149) is a selective metabotropic glutamate type 2 (mGlu2) receptor positive allosteric modulator (PAM) used for the treatment of epilepsy.
Product Name : ADX71149
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 10, 2021